Contact Us
Drug Search Results
More Filters [+]

Mercaptopurine

Alternative Names: mercaptopurine, 6-mercaptopurine, purinethol, puri-nethol, xaluprine, thiopurine, purixan
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Mercaptopurine is a medication used in the management and treatment of acute lymphoblastic leukemia. It is in the class of medications known as purine antagonists. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557620/)

Mechanisms of Action: Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam

Approved Indications: Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia | Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia

Known Adverse Events: Anemia | Thrombocytopenia | Neutropenia | Anorexia | Diarrhea | Leukopenia | Macrophage Activation Syndrome | Lymphoma | T-Cell Lymphoma | Contraception

Company: G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mercaptopurine

Countries in Clinic:

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Colitis, Ulcerative

Phase 2: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
TEMPLE

P2

Active, not recruiting

Oncology Solid Tumor Unspecified

2024-02-08

OPTIC

P3

Active, not recruiting

Colitis, Ulcerative

2019-10-13

Recent News Events

Date

Type

Title

10/31/2024

News Article

 ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)

10/29/2024

News Article

 Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA®  (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting

10/28/2024

News Article

 Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease

10/16/2024

News Article

 Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions